MedPath

Tagged News

MEDSIR and Ataraxis AI Launch Strategic Collaboration to Integrate AI Platform in Breast Cancer Clinical Trials

AIPrecision Medicine
  • MEDSIR and Ataraxis AI have announced a strategic collaboration to integrate artificial intelligence into multiple major international breast cancer trials involving data from more than 1,000 patients.
  • The partnership will evaluate Ataraxis Breast, an AI-native platform that combines digital pathology slides with clinical data to predict patient outcomes and treatment effects across HR+ and HER2+ breast cancer subtypes.
  • The collaboration aims to identify biomarkers that can optimize treatment strategies for breast cancer, including therapies with CDK4/6 inhibitors and antibody-drug conjugates.
  • This partnership represents a significant milestone for Ataraxis Breast, moving beyond retrospective observational studies into prospective trials investigating new therapies.

UC Davis Scientists Develop Precision Gene Therapy for Kaposi's Sarcoma Using Viral "Trojan Horse" Strategy

Precision MedicineTargeted Therapy
  • UC Davis researchers have developed a highly targeted gene therapy that uses an adeno-associated virus to selectively destroy cancer cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) while sparing healthy tissue.
  • The therapy exploits the viral protein LANA, found only in KSHV-infected cells, to activate a modified thymidine kinase enzyme that converts ganciclovir into a potent cancer-killing agent.
  • Preclinical studies in mouse models demonstrated significant tumor growth reduction with no detectable side effects, offering hope for safer treatment of KSHV-related cancers affecting immunocompromised patients.
  • The research, published in Molecular Therapy Oncology, represents a paradigm shift toward precision oncology by turning the virus's own biology against itself.

Empatica Acquires PKG Health to Advance Digital Parkinson's Disease Monitoring

Precision Medicine
  • Empatica has acquired PKG Health, combining FDA-cleared wearable technology with validated movement disorder algorithms to create a comprehensive Parkinson's disease monitoring solution.
  • PKG Health's algorithms, validated in over 70 peer-reviewed studies, monitor bradykinesia, dyskinesia, tremors, and other movement-related signals across 150 hospitals and clinical sites globally.
  • The acquisition addresses the urgent need for objective Parkinson's measures in clinical trials, where despite a robust drug development pipeline, only limited disease-modifying treatments reach Phase 3.
  • The combined platform aims to serve 10 million people living with Parkinson's worldwide through earlier diagnosis, personalized treatment plans, and improved patient outcomes.

Aerska Raises $21M to Develop RNA Therapies for Brain Diseases Using Novel Delivery Platform

Precision Medicine
  • Irish biotech startup Aerska has secured $21 million in seed funding to develop RNA interference therapies targeting degenerative neurological diseases including Alzheimer's and Parkinson's disease.
  • The company's antibody-oligo conjugate platform uses "brain shuttles" to overcome the blood-brain barrier challenge that has limited RNA therapeutics in the central nervous system.
  • Aerska aims to systemically deliver RNA medicines that can silence harmful genes in the brain, potentially treating, delaying, and preventing the onset of neurological diseases.
  • The funding round was co-led by Backed VC, Age1, and Speedinvest, with the company planning to expand operations in Dublin and London while advancing its drug discovery timeline.

RefleXion's SCINTIX Platform Achieves 100% Local Control in Lung and Bone Metastases Trial

Precision MedicineFDA ApprovalOncology
  • RefleXion Medical's SCINTIX biology-guided radiotherapy platform demonstrated 100% local disease control in patients with lung and bone metastases during the nine-month follow-up period of the PREMIER trial.
  • The study showed that 41% of patients achieved complete or partial responses, with 47% of bone metastases patients and 35% of lung tumor patients obtaining these favorable outcomes.
  • SCINTIX represents the first precision radiotherapy system to combine PET imaging with a linear accelerator, enabling real-time biology-guided radiation delivery while maintaining excellent safety profiles.
  • The platform received FDA approval in 2023 and has secured Medicare reimbursement coverage, positioning it as a potential first-in-class treatment option for both localized and metastatic disease.

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System

NCT05406167Recruiting
RefleXion Medical
Posted 4/12/2022

Kynexis Initiates Phase 2 Trial of First-in-Class KAT-II Inhibitor for Schizophrenia-Associated Cognitive Impairment

Precision Medicine
  • Kynexis has dosed the first patient in a Phase 2 clinical trial evaluating KYN-5356, a first-in-class KAT-II inhibitor, for cognitive impairment associated with schizophrenia.
  • The randomized, double-blind, placebo-controlled trial will enroll approximately 150 adults with schizophrenia across 13 U.S. clinical sites over a 28-day treatment period.
  • KYN-5356 demonstrated excellent safety, adequate CNS penetration, and dose-dependent reductions in cerebrospinal fluid kynurenic acid in Phase 1 trials.
  • Topline results from this proof-of-concept study are expected by Q4 2026, addressing an unmet medical need with no currently approved treatments for CIAS.

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

NCT04025502Completed
ERP Biomarker Qualification Consortium
Posted 10/7/2019

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

NCT07191483RecruitingNot Applicable
Kynexis B.V.
Posted 8/27/2025

Inflammatix Publishes Breakthrough Sepsis Research in Nature Medicine, Validates AI-Powered TriVerity Test

AIPrecision Medicine
  • Inflammatix published three landmark studies in Nature Medicine that redefine sepsis diagnosis and treatment through AI-powered immune profiling and consensus frameworks.
  • The SEPSIS-SHIELD study validated TriVerity's ability to distinguish bacterial from viral infections and predict illness severity in over 1,200 patients with high sensitivity and specificity.
  • Two new consensus frameworks, HI-DEF and CTS, identified distinct immunological states in sepsis patients, with dysregulated patients showing 5-7 times higher mortality risk.
  • TriVerity received FDA 510(k) clearance in January 2025 and delivers results in 30 minutes to guide emergency department triage decisions.

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

NCT04094818Completed
Inflammatix
Posted 2/28/2020

Bio-Techne Expands Oxford Nanopore Partnership Through 2032 for Advanced Genetic Diagnostics

Precision Medicine
  • Bio-Techne Corporation has extended its collaboration with Oxford Nanopore Technologies through 2032, expanding development of targeted genetic testing kits for heritable disorder screening and diagnosis.
  • The partnership builds on the successful 2025 launch of the AmplideX Nanopore Carrier Plus Kit, demonstrating Bio-Techne's strategic push into advanced genetic diagnostics.
  • The company also unveiled enhanced spatial biology technologies including RNAscope™ ISH technology and Lunaphore COMET™ solutions for simultaneous RNA and protein biomarker detection.
  • Bio-Techne projects $1.5 billion in revenue and $250.1 million in earnings by 2028, requiring 6.5% annual revenue growth despite ongoing biotech funding pressures.

Kardigan Secures $254 Million Series B to Advance Three Late-Stage Cardiovascular Programs

Precision Medicine
  • Kardigan closed a $254 million Series B financing round led by Fidelity Management & Research Company and T. Rowe Price Investment Management to advance three late-stage cardiovascular programs.
  • The company's pipeline targets dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis with potential first-in-class therapies designed to address disease at its biological source.
  • Multiple data readouts are expected beginning in 2026, positioning Kardigan to deliver functional cures rather than symptom management for life-threatening cardiovascular conditions.
  • The funding supports a precision medicine approach using "cardiac intelligence" to develop personalized therapies for specific patient subsets in diseases that currently lack effective treatments.

Lunai Bioworks Advances AI-Powered Parkinson's Biomarker Discovery Program for Strategic Pharma Partnerships

AIPrecision MedicineDrug Discovery
  • Lunai Bioworks has advanced its preclinical biomarker discovery program for Parkinson's Disease using its subsidiary BioSymetrics' proprietary Augusta Platform, positioning the initiative for strategic pharmaceutical partnerships.
  • The program leverages phenogrouping technology to identify distinct patient subtypes with greater precision, enabling targeted therapeutic development in a market affecting over 10 million people globally.
  • The company's approach has received validation through a competitive STTR grant from the National Institutes of Health and recognition from the Michael J. Fox Foundation.
  • With Parkinson's incidence expected to double by 2050, the expanding patient population represents a significant unmet medical need and compelling opportunity for therapeutic innovation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.